AP2006003786A0 - Tetrahydronaphthyridine derivatives useful as histamine H3 receptor ligands - Google Patents

Tetrahydronaphthyridine derivatives useful as histamine H3 receptor ligands

Info

Publication number
AP2006003786A0
AP2006003786A0 AP2006003786A AP2006003786A AP2006003786A0 AP 2006003786 A0 AP2006003786 A0 AP 2006003786A0 AP 2006003786 A AP2006003786 A AP 2006003786A AP 2006003786 A AP2006003786 A AP 2006003786A AP 2006003786 A0 AP2006003786 A0 AP 2006003786A0
Authority
AP
ARIPO
Prior art keywords
histamine
receptor ligands
derivatives useful
tetrahydronaphthyridine derivatives
tetrahydronaphthyridine
Prior art date
Application number
AP2006003786A
Other languages
English (en)
Inventor
Graham Lunn
John Paul Mathias
Ros Sinclair Strang
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of AP2006003786A0 publication Critical patent/AP2006003786A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Otolaryngology (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AP2006003786A 2004-05-12 2005-05-06 Tetrahydronaphthyridine derivatives useful as histamine H3 receptor ligands AP2006003786A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04291222A EP1595881A1 (en) 2004-05-12 2004-05-12 Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands
PCT/IB2005/001267 WO2005111036A1 (en) 2004-05-12 2005-05-06 Tetrahydronaphthyridine derivatives useful as histamine h3 receptor ligands

Publications (1)

Publication Number Publication Date
AP2006003786A0 true AP2006003786A0 (en) 2006-10-31

Family

ID=34931096

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2006003786A AP2006003786A0 (en) 2004-05-12 2005-05-06 Tetrahydronaphthyridine derivatives useful as histamine H3 receptor ligands

Country Status (32)

Country Link
US (2) US7557121B2 (es)
EP (2) EP1595881A1 (es)
JP (1) JP4084410B2 (es)
KR (1) KR100908155B1 (es)
CN (2) CN101798305A (es)
AP (1) AP2006003786A0 (es)
AR (1) AR049092A1 (es)
AT (1) ATE491707T1 (es)
AU (1) AU2005243403B2 (es)
BR (1) BRPI0510762A (es)
CA (1) CA2564201C (es)
CR (1) CR8747A (es)
DE (1) DE602005025345D1 (es)
DK (1) DK1756104T3 (es)
EA (1) EA010487B1 (es)
EC (1) ECSP066984A (es)
ES (1) ES2355572T3 (es)
GE (1) GEP20084552B (es)
GT (1) GT200500112A (es)
IL (1) IL178882A (es)
MA (1) MA28579B1 (es)
MX (1) MXPA06013113A (es)
NL (1) NL1029016C2 (es)
NO (1) NO20064577L (es)
PA (1) PA8632801A1 (es)
PE (1) PE20060312A1 (es)
SV (1) SV2005002112A (es)
TN (1) TNSN06369A1 (es)
TW (1) TW200607506A (es)
UY (1) UY28895A1 (es)
WO (1) WO2005111036A1 (es)
ZA (1) ZA200609111B (es)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6468306B1 (en) 1998-05-29 2002-10-22 Advanced Medical Optics, Inc IOL for inhibiting cell growth and reducing glare
US7621949B2 (en) 2003-12-09 2009-11-24 Advanced Medical Optics, Inc. Foldable intraocular lens and method of making
WO2006138714A2 (en) * 2005-06-17 2006-12-28 Janssen Pharmaceutica N.V. Naphthyridine compounds
US8158673B2 (en) * 2005-10-27 2012-04-17 Pfizer Inc. Histamine-3 receptor antagonists
CA2624625A1 (en) * 2005-11-04 2007-05-10 Pfizer Limited Tetrahydronaphthyridine derivative
WO2007099423A1 (en) * 2006-03-02 2007-09-07 Pfizer Products Inc. 1-pyrrolidine indane derivatives as histamine-3 receptor antagonists
KR20080109841A (ko) 2006-03-10 2008-12-17 뉴로젠 코포레이션 피페라지닐 옥소알킬 테트라히드로이소퀴놀린 및 관련유사체
US9108948B2 (en) 2006-06-23 2015-08-18 Abbvie Inc. Cyclopropyl amine derivatives
TW200808773A (en) 2006-06-23 2008-02-16 Abbott Lab Cyclopropyl amine derivatives
US20100266504A1 (en) * 2007-11-15 2010-10-21 Takahiro Matsumoto Condensed pyridine derivative and use thereof
US8383657B2 (en) 2007-12-21 2013-02-26 Abbott Laboratories Thiazolylidine urea and amide derivatives and methods of use thereof
WO2009082698A1 (en) * 2007-12-21 2009-07-02 Abbott Laboratories Compositions for treatment of cognitive disorders
US20110190263A1 (en) * 2008-02-22 2011-08-04 Irm Llc Compounds and compositions as modulators of gpr119 activity
CA2719985A1 (en) * 2008-03-31 2009-10-08 Evotec Ag Tetrahydronaphthyridines and aza derivatives thereof as histamine h3 receptor antagonists
WO2010026113A1 (en) * 2008-09-03 2010-03-11 Evotec Neurosciences Gmbh Acyl- and sufonyl tetrahydronaphthyridines and aza derivatives thereof as histamine h3 receptor antagonists
WO2010052222A1 (en) * 2008-11-07 2010-05-14 Evotec Neurosciences Gmbh (dihydro)naphthyridinone derivatives as histamine h3 receptor antagonists
WO2010122064A1 (en) * 2009-04-21 2010-10-28 Neurosearch A/S Substituted naphthyridine derivatives and their medical use
US9186353B2 (en) 2009-04-27 2015-11-17 Abbvie Inc. Treatment of osteoarthritis pain
US8711772B2 (en) * 2009-05-22 2014-04-29 Qualcomm Incorporated Paging of a user equipment (UE) within a wireless communications system
WO2011005636A1 (en) * 2009-07-09 2011-01-13 Merck Sharp & Dohme Corp. Tetrahydronapthyridine orexin receptor antagonists
US8853390B2 (en) 2010-09-16 2014-10-07 Abbvie Inc. Processes for preparing 1,2-substituted cyclopropyl derivatives
CN102093356B (zh) * 2011-03-16 2012-12-19 无锡美克赛医药科技有限公司 一种2-氯-5,6,7,8-四氢-1,6-萘啶盐酸盐的制备方法
WO2012131539A1 (en) 2011-03-31 2012-10-04 Pfizer Inc. Novel bicyclic pyridinones
WO2012172449A1 (en) 2011-06-13 2012-12-20 Pfizer Inc. Lactams as beta secretase inhibitors
JP6043355B2 (ja) 2011-08-31 2016-12-14 ファイザー・インク ヘキサヒドロピラノ［３，４−ｄ］［１，３］チアジン−２−アミン化合物
EP2852597B1 (en) 2012-05-04 2016-06-08 Pfizer Inc Heterocyclic substituted hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds as inhibitors of app, bace1 and bace 2.
CN105732639A (zh) 2012-06-29 2016-07-06 辉瑞大药厂 作为LRRK2抑制剂的4-(取代的氨基)-7H-吡咯并〔2,3-d〕嘧啶类
JP2015529239A (ja) 2012-09-20 2015-10-05 ファイザー・インク アルキル置換ヘキサヒドロピラノ［３，４−ｄ］［１，３］チアジン−２−アミン化合物
UA110688C2 (uk) 2012-09-21 2016-01-25 Пфайзер Інк. Біциклічні піридинони
WO2014091352A1 (en) 2012-12-11 2014-06-19 Pfizer Inc. Hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds as inhibitors of bace1
US9403846B2 (en) 2012-12-19 2016-08-02 Pfizer Inc. Carbocyclic- and heterocyclic-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
CA2897678A1 (en) 2013-02-13 2014-08-21 Pfizer Inc. Heteroaryl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
US9233981B1 (en) 2013-02-15 2016-01-12 Pfizer Inc. Substituted phenyl hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
MX2015010714A (es) 2013-02-19 2016-06-14 Pfizer Compuestos de azabencimidazol.
MX2015015163A (es) 2013-05-02 2016-02-22 Pfizer Derivados de imidazo-triazina como inhibidores de pde10.
CA2925743C (en) 2013-10-04 2018-03-06 Pfizer Inc. Novel bicyclic pyridinones as gamma-secretase modulators
EP3083618B1 (en) 2013-12-17 2018-02-21 Pfizer Inc Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors
MD20160102A2 (ro) 2014-04-01 2017-04-30 Pfizer Inc. Cromen şi 1,1a,2,7b-tetrahidrociclopropa[c]cromen piridopirazindione ca modulatori ai gama-secretazei
AP2016009493A0 (en) 2014-04-10 2016-10-31 Pfizer 2-AMINO-6-METHYL-4,4a,5,6-TETRAHYDROPYRANO[3,4-d][1,3]THIAZIN-8a(8H)-YL-1,3-THIAZOL-4-YL AMIDES
EP3172210B1 (en) 2014-07-24 2020-01-15 Pfizer Inc Pyrazolopyrimidine compounds
KR102061952B1 (ko) 2014-08-06 2020-01-02 화이자 인코포레이티드 이미다조피리다진 화합물
PE20171318A1 (es) 2015-02-03 2017-09-07 Pfizer Ciclopropabenzofuranil-piridopirazindionas novedosas
AU2016267141B2 (en) * 2015-05-28 2020-04-16 Theravance Biopharma R&D Ip, Llc Naphthyridine compounds as jak kinase inhibitors
WO2016203347A1 (en) 2015-06-17 2016-12-22 Pfizer Inc. Tricyclic compounds and their use as phosphodiesterase inhibitors
JP6873980B2 (ja) 2015-09-14 2021-05-19 ファイザー・インク ＬＲＲＫ２阻害薬としての新規のイミダゾ［４，５−ｃ］キノリンおよびイミダゾ［４，５−ｃ］［１，５］ナフチリジン誘導体
WO2017051294A1 (en) 2015-09-24 2017-03-30 Pfizer Inc. N-[2-(3-amino-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2h-1,2,4-thiadiazin-5-yl)-1,3-thiazol-4-yl] amides useful as bace inhibitors
WO2017051276A1 (en) 2015-09-24 2017-03-30 Pfizer Inc. N-[2-(2-amino-6,6-disubstituted-4, 4a, 5, 6-tetrahydropyrano [3,4-d][1,3] thiazin-8a (8h)-yl) -1, 3-thiazol-4-yl] amides
JP2018531924A (ja) 2015-09-24 2018-11-01 ファイザー・インク テトラヒドロピラノ［３，４−ｄ］［１，３］オキサジン誘導体、およびｂａｃｅ阻害剤としてのその使用
AU2017223132B2 (en) 2016-02-23 2019-12-05 Pfizer Inc. 6,7-Dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds
CN109641898B (zh) 2016-07-01 2022-04-08 辉瑞公司 用于治疗神经和神经退行性疾病的5,7-二氢-吡咯并-吡啶衍生物
IL269215B (en) 2017-03-10 2022-09-01 Pfizer Disubstituted imidazole[4,5-c]quinoline derivatives
CA3056030A1 (en) 2017-03-10 2018-09-13 Pfizer Inc. Novel imidazo[4,5-c]quinoline derivatives as lrrk2 inhibitors
WO2018226992A1 (en) 2017-06-07 2018-12-13 Adrx, Inc. Tau aggregation inhibitors
AU2018287787A1 (en) 2017-06-22 2020-01-16 Pfizer Inc. Dihydro-pyrrolo-pyridine derivatives
EP3668886A2 (en) 2017-08-18 2020-06-24 Adrx, Inc. Tau aggregation peptide inhibitors
HUE061533T2 (hu) 2018-03-23 2023-07-28 Pfizer Piperazin azaspiro származékok

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
WO1997029092A1 (en) 1996-02-09 1997-08-14 James Black Foundation Limited Histamine h3 receptor ligands
WO2000035298A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing gum containing medicament active agents
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
GB9803536D0 (en) * 1998-02-19 1998-04-15 Black James Foundation Histamine H,receptor ligands
EP0982300A3 (en) 1998-07-29 2000-03-08 Societe Civile Bioprojet Non-imidazole alkylamines as histamine H3 - receptor ligands and their therapeutic applications
TWI298068B (en) * 2000-06-21 2008-06-21 Dainippon Sumitomo Pharma Co Pharmaceutical composition for schizophrenia
DE60130460T2 (de) 2000-07-13 2008-06-05 Abbott Laboratories, Abbott Park 1,3-disubstituierte und 1,3,3-trisubstituierte pyrrolidine als liganden des histamin-3 rezeptors und ihre therapeutischen anwendungen
MXPA03001268A (es) 2000-08-08 2004-09-06 Johnson & Johnson Ariloxipiperidinas sin imidazol.
DE60117814T2 (de) * 2000-08-08 2006-11-02 Ortho-Mcneil Pharmaceutical, Inc. Nicht-imidazol aryloxyalkylamine als h3 rezeptor liganden
AU2002254114A1 (en) 2001-03-23 2002-10-08 Eli Lilly And Company Non-imidazole aryl alkylamines compounds as histamine h3 receptor antagonists, preparation and therapeutic uses
GB0206033D0 (en) * 2002-03-14 2002-04-24 Pfizer Ltd Compounds useful in therapy
AU2004259263B2 (en) * 2003-07-29 2010-12-16 High Point Pharmaceuticals, Llc Pyridazinyl- piperazines and their use as histamine H3 receptor ligands
CA2624625A1 (en) * 2005-11-04 2007-05-10 Pfizer Limited Tetrahydronaphthyridine derivative

Also Published As

Publication number Publication date
AR049092A1 (es) 2006-06-28
TW200607506A (en) 2006-03-01
MA28579B1 (fr) 2007-05-02
SV2005002112A (es) 2005-12-13
NL1029016A1 (nl) 2005-11-15
CA2564201A1 (en) 2005-11-24
ATE491707T1 (de) 2011-01-15
GEP20084552B (en) 2008-11-25
NO20064577L (no) 2006-11-06
TNSN06369A1 (fr) 2008-02-22
NL1029016C2 (nl) 2006-05-30
DK1756104T3 (da) 2011-02-21
CR8747A (es) 2006-12-05
EP1595881A1 (en) 2005-11-16
BRPI0510762A (pt) 2007-11-20
CN1950371A (zh) 2007-04-18
PA8632801A1 (es) 2006-06-02
PE20060312A1 (es) 2006-05-03
ZA200609111B (en) 2008-08-27
AU2005243403A1 (en) 2005-11-24
EA010487B1 (ru) 2008-10-30
DE602005025345D1 (de) 2011-01-27
IL178882A0 (en) 2007-03-08
CA2564201C (en) 2011-01-18
ECSP066984A (es) 2006-12-29
JP4084410B2 (ja) 2008-04-30
KR20070014174A (ko) 2007-01-31
US20090258861A1 (en) 2009-10-15
MXPA06013113A (es) 2007-02-28
KR100908155B1 (ko) 2009-07-16
US7557121B2 (en) 2009-07-07
CN1950371B (zh) 2011-01-12
US20050256135A1 (en) 2005-11-17
ES2355572T3 (es) 2011-03-29
AU2005243403B2 (en) 2010-10-07
CN101798305A (zh) 2010-08-11
EP1756104A1 (en) 2007-02-28
JP2007536374A (ja) 2007-12-13
EA200601897A1 (ru) 2007-02-27
UY28895A1 (es) 2005-12-30
GT200500112A (es) 2005-12-12
IL178882A (en) 2011-03-31
EP1756104B1 (en) 2010-12-15
WO2005111036A1 (en) 2005-11-24

Similar Documents

Publication Publication Date Title
ZA200609111B (en) Tetrahydronaphthyridine derivatives useful as histamine H3 receptor ligands
IL180548A0 (en) Piperidine derivatives as histamine h3 receptor ligands
SI1802307T1 (sl) Derivati pirolidina kot ligandi histaminskih receptorjev
TWI369356B (en) Tetrahydropyridoindole derivatives
ZA200703912B (en) 3-arylamino pyridine derivatives
IL180430A0 (en) Pyridine derivatives
IL180481A0 (en) Aryl-pyridine derivatives
HK1105971A1 (en) Pyrrazolo-pyrimidine derivatives
GB0512335D0 (en) Merocyanine derivatives
ZA200703172B (en) Imidazo-benzodiazepine derivatives
HK1100002A1 (en) 4-phenyl-pyrimidine-2-carbonitrile derivatives
EP1713917A4 (en) PNEUMOLYSINE DERIVATIVES
HK1092469A1 (en) Benzothiazole derivatives as adenosine receptor ligands
HK1100775A1 (en) 4-Amino-5-cyanopyrimidine derivatives
GB0414272D0 (en) OsK1 derivatives
IL188924A0 (en) Imidazopyridine derivatives as cannabinoid receptor ligands
ZA200705106B (en) Nicotinic acetycholine receptor ligands
IL182001A0 (en) 2-acylaminothiazole derivatives
ZA200800354B (en) Imidazopyridine derivatives as cannabinoid receptor ligands
GB0411078D0 (en) Bicyclic derivatives
GB0416524D0 (en) Pyridine derivatives
ZA200600676B (en) Pyridazinyl-piperazines and their use as histamine H3 receptor ligands
GB0405905D0 (en) Azaquinazoline derivatives
GB0422397D0 (en) 3-Cyano-Quinoline derivatives